Log in to search using one of your social media accounts:

This page shows you the latest news items in this category. This is page number 12.

Treat-to-Target the New Goal in Lupus
(MedPage Today) -- An international task force has taken the first steps toward formulating a "treat to target" approach for the treatment of systemic lupus erythematosus (SLE), focusing on remission, damage prevention, and quality of life. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 18, 2014 Category: Primary Care Source Type: news

10 Common Mistakes in the Management of Lupus Nephritis10 Common Mistakes in the Management of Lupus Nephritis
Are the most common ways to treat lupus nephritis necessarily the most effective and the safest? This new study takes a look. American Journal of Kidney Diseases (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - April 18, 2014 Category: Urology & Nephrology Tags: Nephrology Journal Article Source Type: news

Smoking Tied to Worse Lupus, Arthritis (CME/CE)
(MedPage Today) -- Worse patterns of disease for both rheumatoid arthritis and systemic lupus erythematosus were seen among patients who were smokers, and the risks actually increased after quitting for those with lupus, Swedish researchers reported. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 13, 2014 Category: Geriatrics Source Type: news

Stem Cells Seen as Promising in Lupus (CME/CE)
(MedPage Today) -- Mesenchymal stem cell transplantation is showing promise as a treatment for refractory systemic lupus erythematosus, researchers have reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 11, 2014 Category: Primary Care Source Type: news

In Vivo Cell Transfer Assay to Detect Autoreactive T Cell Subsets
Among the methods used in molecular biology, in vitro biochemical assays are more common, whereas in vivo assays, including the use of animal models, are less widely employed. In our studies on systemic lupus erythematosus (SLE), we have identified a novel T cell subtype termed “autoantibody-inducing CD4 T cells” (aiCD4 T cell) that is responsible for the development of autoimmunity. In order to identify and isolate these cells, we developed a new technique that involves the transfer of candidate T cell subpopulations into naïve mice and assaying for the development of autoantibodies in the recipient mice....
Source: Springer protocols feed by Molecular Medicine - April 7, 2014 Category: Molecular Biology Source Type: news

Induction of De Novo Autoimmune Disease in Normal Mice upon Repeated Immunization with Antigen
We describe here a novel and completely reproducible experimental technique that can induce systemic autoimmunity or systemic lupus erythematosus (SLE) in mice otherwise not prone to spontaneous autoimmune disease. This protocol involves the repeated immunization of mice with the same antigen. This rather simple technique enables us to perform exact and quantitative in vivo animal experiments with great accuracy. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - April 7, 2014 Category: Molecular Biology Source Type: news

What is Lupus: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Vaidehi Chowdhary explain lupus. To listen, click the link below. What is Lupus   (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2014 Category: Databases & Libraries Source Type: news

Shingles Vaccine OK in Mild Lupus
NEW YORK (MedPage Today) -- Vaccination against shingles may be safe for patients with mild, stable systemic lupus erythematosus, a researcher said here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 24, 2014 Category: Geriatrics Source Type: news

Primary Cardiac Disease Still Occurs in Lupus
(MedPage Today) -- Pericarditis and other forms of primary cardiac disease can occur at any time during the course of systemic lupus erythematosus, but antimalarial treatment can be protective, South American researchers reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 19, 2014 Category: Primary Care Source Type: news

Discounted Systemic Lupus Erythematosus and Lupus Nephritis Treatment...
Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at...(PRWeb March 18, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11679578.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 19, 2014 Category: Pharmaceuticals Source Type: news

Class, ancestry and medication are factors in cardiac risk for lupus patients
New research published in Rheumatology, the international, peer-reviewed scientific journal, has suggested that systemic lupus erythematosus (SLE) patients of African descent and from lower socioeconomic groups face a higher risk of primary cardiac disease. However, those taking anti-malarial drugs reduce their risk.The research found that 14% of patients experience cardiac problems as a result of the auto-immune disorder within five years of diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2014 Category: Consumer Health News Tags: Lupus Source Type: news

What are expectations that can come from the Accelerating Medicines Partnership?
Virginia Ladd - AMP Submitted by Julie on Mon, 03/17/2014 - 12:45 Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. Share Email Print var switchTo5x = false;var __st_loadLate = true;stLight.options({"publisher":"dr-e0d16a36-b72f-d979-d8a1-314a351971a6...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Leslie Hanrahan - AMP
We believe this initiative will ultimately lead to new understanding of the underlying causes of lupus along with new therapies for this disease and ultimately an improved quality of life for people living with lupus. For us it is all about the patient! Lupus is  complex and is arguably the most clinically diverse of all autoimmune diseases. Because of this, the scope of the Accelerating Medicines Partnership (AMP)  is tailor made for a collaborative effort among the NIH, industry, academic medical research centers and non profit organization. Lupus was selected for this project because of the lack of effective targeted ...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Gary Nabel - AMP
It has been said that all boats rise with the tide. That’s the analogy that comes to mind when thinking about the potential of the Accelerating Medicines Partnership (AMP). By bringing together stakeholders from the National Institutes of Health (NIH), biopharmaceutical companies and several non-profit organizations, AMP is a great opportunity for all of us to join together and develop a broad-based understanding about some of the chronic conditions facing patients today. Sanofi is excited to be participating in two of the AMP focus areas: type 2 diabetes and rheumatoid arthritis/lupus. It may seem counterintuitive for 1...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Virginia Ladd - AMP
Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. In existing research, 80-100 different autoimmune diseases have been identified and researchers suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. The American Autoimmune Related Diseases Association (AARD...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

HIV vaccine hope found in immune system of a unique patient
The Journal of Clinical Investigation has published a new study of a unique patient with an immune system that produces the types of neutralizing antibodies that are considered essential to an effective HIV vaccine response.The patient has a rare combination of HIV and systemic lupus erythematosus or SLE, a disease where the immune system attacks the body's own cells and tissue.Senior author Barton F. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2014 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

New Antibody Shows Promise in Lupus
(MedPage Today) -- Initial clinical studies of epratuzumab in patients with active, moderate-to-severe systemic lupus erythematosus are suggesting promise for this monoclonal antibody. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 12, 2014 Category: Primary Care Source Type: news

Vaccine hope for HIV offered by unique individual's immune response to virus
One person's unique ability to fight HIV has provided key insights into an immune response that researchers now hope to trigger with a vaccine, according to findings reported by a team that includes Duke Medicine scientists.The person had a rare combination of both lupus and HIV. Lupus, specifically systemic lupus erythematosus, or SLE, is a disease in which the immune system attacks the body's cells and tissue. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

Paid Lupus Clinical Trial Now Enrolling at Achieve Clinical Research...
Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with...(PRWeb March 11, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11643043.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 11, 2014 Category: Pharmaceuticals Source Type: news

Jury Awards Lupus Sufferer $800,000 For Insurer's Bad Faith Coverage Denial
SAN FRANCISCO - After an eight-day trial, a California federal jury on Feb. 13 found that an insurer breached its contract and acted in bad faith by denying long-term disability (LTD) coverage to a woman diagnosed with lupus, awarding her more than $873,622 in unpaid benefits and compensatory damages (Cassaundra Ellena v. Standard Insurance Co., et al., No. 3:12-cv-05401, N.D. Calif.). (Source: LexisNexis® Mealey's™ Disability Insurance Legal News)
Source: LexisNexis® Mealey's™ Disability Insurance Legal News - March 11, 2014 Category: Medical Law Source Type: news

Unique individual with lupus and HIV demonstrates desired immune response to HIV
One person’s unique ability to fight HIV has provided key insights into an immune response that researchers now hope to trigger with a vaccine, according to new findings. The person had a rare combination of both lupus and HIV. Lupus, specifically systemic lupus erythematosus, or SLE, is a disease in which the immune system attacks the body's cells and tissue. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 10, 2014 Category: Science Source Type: news

JCI online ahead of print table of contents for March 10, 2014
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, March 10, 2014 in the JCI: 'Identification of a broadly neutralizing HIV-1 antibody in a lupus patient,' 'Evaluating disease-associated protein turnover kinetics,' 'Transport properties of pancreatic cancer describe gemcitabine delivery and response,' 'HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers,' 'iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions,' and more. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 10, 2014 Category: Global & Universal Source Type: news

Medical Marijuana not Recommended for Rheumatoid Arthritis, Lupus, or Fibromyalgia Symptoms
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy. (Source: Disabled World)
Source: Disabled World - March 9, 2014 Category: Disability Tags: Medical Marijuana Source Type: news

Researchers discourage rheumatology patients from using cannabis
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 6, 2014 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Leslie Hanrahan
Vice President, Education and Research of the Lupus Foundation of America, Inc.Leslie Hanrahan has over 22 years’ experience in health communications, education and research programming. Since 2005, Ms. Hanrahan has led the strategic development and growth of the Education and Research Department of the Lupus Foundation of America (LFA).  The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact.  Prior to joining the LFA, Ms. Hanrah...
Source: PHRMA - March 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news

How Wolves Change Rivers | video | @GrrlScientist
Wolves are top predators that have far-reaching beneficial effects upon entire ecosystems -- including the structure of rivers.Wolves are crucial for maintaining a healthy ecosystem -- a fact that was conveniently forgotten when they were exterminated from almost all of the continental United States by ranchers, farmers, trappers and hunters.Meanwhile, the populations of other animals exploded. The entire ecosystem of the American wilderness was changed by exploding populations of large ungulates -- particularly wapiti, Cervus canadensis. (These animals are more commonly known as "elk" -- note that the narrator in the acco...
Source: Guardian Unlimited Science - March 3, 2014 Category: Science Authors: GrrlScientist Tags: theguardian.com Blogposts Biology National parks Animals Plants Zoology Environment Science Source Type: news

Herbal cannabis not recommended for rheumatology patients
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 3, 2014 Category: Science Source Type: news

What are some realistic expectations that can come from the Accelerating Medicines Partnership?
Opinionconversations48254827Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. In existing research, 80-100 different autoimmune diseases have been identified and researchers suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. The American Autoimmune Relate...
Source: PHRMA - February 26, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Virginia T. Ladd
President & Executive Director, American Autoimmune Related Diseases Association, Inc. Virginia T. Ladd, R.T. – Virginia Ladd is the President and Executive Director of the American Autoimmune Related Diseases Association, Inc. (AARDA), an organization that she founded to bring a national focus to autoimmunity and increase collaboration in autoimmune research, education, awareness, and advocacy. She has been involved in the nonprofit community for over 30 years as a patient advocate and educator. Mrs. Ladd served as president and executive director of the Lupus Foundation of America. Mrs. Ladd was instrumental in the...
Source: PHRMA - February 26, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

What are our greatest challenges as we address managing chronic diseases like diabetes?
conversationsphrmapediaOpinion480448091404Despite many attempts by prominent researchers utilizing different approaches, there is no cure for diabetes. While continuing extensive research looking into “the cure”, much work is being conducted in the day –to- day management of diabetes. As such, it is essential to develop treatments that not only help measure and adjust blood glucose levels- thus preventing hyper and hypoglycemia, but also to improve the quality of life in our patients with diabetes. The amount of self care skills required to manage diabetes is extensive, requiring blood glucose monitoring, insulin inj...
Source: PHRMA - February 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Progression From Cutaneous to Systemic Lupus Erythematosus Progression From Cutaneous to Systemic Lupus Erythematosus
Most patients who progress from cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus (SLE) do not develop significant systemic manifestations, according to a longitudinal study. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 8, 2014 Category: Dermatology Tags: Dermatology News Source Type: news

Measuring Interferon Alpha and Other Cytokines in SLE
We describe a functional assay to measure type I IFN activity in SLE plasma and have also measured the response of peripheral blood cells to that cytokine family. This method can be scaled to assess IFN functional activity, as well as activity and cellular response to other cytokines, in relation to cellular and serologic parameters relevant to SLE. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Induced Murine Models of Systemic Lupus Erythematosus
Induced mouse models of systemic lupus erythematosus (SLE) have been developed to complement the spontaneous models. This chapter describes the methods used in the pristane-induced model and the chronic graft-versus-host disease (cGVHD) model, both of which have been extensively used. We will also outline the specific mechanisms of systemic autoimmunity that can be best characterized using each of these models. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

TLC Immunostaining for Detection of “Antiphospholipid” Antibodies
Thin-layer chromatography (TLC) is a nonquantitative technique, which has been employed in the detection of antiphospholipid (aPL) antibodies. Antiphospholipid syndrome (APS) is the most frequently acquired thrombophilia, characterized by thrombosis and obstetric manifestations associated to an autoimmune trait, represented by the positivity of antiphospholipid (aPL) antibodies. Immunoassays for anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) antibodies and clotting tests for lupus anticoagulant (LA) represent the standard tests for the routine detection of aPL. The term “seronegative APS” h...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Bifunctional Antibody Fragment-Based Fusion Proteins for the Targeted Elimination of Pathogenic T-Cell Subsets
Pathogenic effector T cells are key contributors to autoimmune diseases such as systemic lupus erythematosus (SLE). General inhibition of T cells using, e.g., methotrexate, prednisolone, or TNF blockers, has prominent therapeutic effects frequently at the cost of severe long-term side effects and toxicity. Therefore, targeted strategies that can selectively inhibit or eliminate pathogenic T cells are sought after as a new approach to safely block perpetual inflammatory T-cell responses and inhibit concomitant progressive tissue destruction. Of particular interest in this respect is the use of the so-called single-chain fra...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Measurement of Malondialdehyde, Glutathione, and Glutathione Peroxidase in SLE Patients
Oxidative stress contributes to chronic inflammation of tissues and plays a central role in immunomodulation, which may lead to autoimmune diseases such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome. Markers of oxidative damage include malondialdehyde (MDA), antioxidant scavengers as glutathione (GSH), and glutathione peroxidase (GSH Px), which all correlate well with SLE disease activity. Amelioration of some clinical manifestations of SLE may be expected by targeting lipid peroxidation with dietary or pharmacological antioxidants. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Generation of Self-Peptides to Treat Systemic Lupus Erythematosus
Synthetic peptides are attracting increasing attention as therapeutics. Despite their potential, however, only a few selected peptides have been able to enter in clinical trials for chronic autoimmune diseases and systemic lupus erythematosus (SLE) in particular. Here, we describe and discuss a series of assays, which may help in characterizing valuable candidate peptides that were applied in our laboratory to develop the lupus P140 peptide program. The different steps of selection include the choice of the initial autoantigen, the design, synthesis and purification of peptides, their preliminary screen by measuring cytoki...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Detection of SLE Antigens in Neutrophil Extracellular Traps (NETs)
Neutrophils are sentinel cells of the innate immune system with a primary role of clearing extracellular pathogens. The release of weblike structures decorated with granular proteins called neutrophil extracellular traps (NETs) has recently been implicated in the pathogenesis of inflammatory and autoimmune diseases. Indeed, NETs may represent an important source of autoantigens and immunostimulatory proteins in systemic lupus erythematosus (SLE). In this chapter, we describe protocols to isolate human peripheral neutrophils, to generate and isolate NETs, and to detect SLE antigens in NETs using immunofluorescence and immun...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Isolation, Polarization, and Expansion of CD4+ Helper T Cell Lines and Clones Using Magnetic Beads
Autoreactive CD4+ helper T cells specific for a range of nucleoprotein-derived autoantigens are an important feature of systemic lupus erythematosus, driving B cell differentiation and autoantibody production and contributing to the inflammatory lesions caused by immune complex deposition. Several peptide epitopes from nucleoprotein antigens have been identified and offer a means selectively to manipulate T cell responses by skewing toward a profile of cytokines that is less pro-inflammatory. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Meta-analysis as a Diagnostic Tool for Predicting Disease Onset and/or Activity in Systemic Lupus Erythematosus
Systemic lupus erythematous (SLE) is a relatively rare disorder with prevalence rates between 5 and 50 per 100,000 population. This means performing any epidemiological analysis in a specific research center is difficult, due to the low number of cases within any one location. There is a need for biomarkers and diagnostic aids to monitor SLE disease activity and severity prior, during, and after treatment. Many specialist lupus clinics worldwide have published trials following in detail small numbers of patients that have been monitored for a disease biomarker, e.g., an autoantibody against a self-molecule in prospective a...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Microarray Technology for Analysis of MicroRNA Expression in Renal Biopsies of Lupus Nephritis Patients
This article offers a technological overview of microarray technology for analysis of microRNA gene expression in kidney biopsies from SLE patients. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Laboratory Tests for the Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) in the presence of persistent antiphospholipid antibodies (aPL), detected by lupus anticoagulant (LA), anticardiolipin (aCL) antibody, and/or anti‐β2 glycoprotein I (aβ2GPI) antibody assays. These aPL, considered to be diagnostic markers and pathogenic drivers of APS, are a heterogeneous group of antibodies directed against anionic phospholipids, phospholipid-binding plasma proteins, and phospholipid–protein complexes. Although APS is currently considered as a s...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Evaluating a Particular Circulating MicroRNA Species from an SLE Patient Using Stem-Loop qRT-PCR
Systemic lupus erythematosus (SLE) is a complex autoimmune disease, and correct judgment of SLE activity is very important in guiding precise clinical treatment. Circulating microRNAs (miRNAs) could serve as potential biomarkers of disease activity or status in SLE, and here we describe a modified qRT-PCR method for detecting them. Stem loop has become one of the most powerful methods for determining miRNA expression because it is highly sensitive and accurate and requires only small amount of sample. In this chapter, we focus on a stem-loop reverse transcription-bound SYBR green qRT-PCR protocol for evaluating a particula...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

The Lupus Biomarker Odyssey: One Experience
The last decade has witnessed an explosion in efforts to discover and validate lupus biomarkers. The currently steep trajectory of this progress is unprecedented. However, advances in the lupus biomarker field remain fewer and slower than physicians, patients, and pharmaceutical companies have hoped for. This chapter will review the challenges confronted by physicians and scientists in pursuit of lupus biomarkers and will present our experience on this path and specific efforts to surmount some of the obstacles in this endeavor. A comprehensive review of the current landscape in lupus biomarker research has recently been p...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Pathology of Systemic Lupus Erythematosus: The Challenges Ahead
Many studies have explored the pathology of systemic lupus erythematosus (SLE), an autoimmune rheumatic disorder with a striking female predominance. Numerous autoimmune phenomena are present in this disease, which ultimately result in organ damage. However, the specific cellular and humoral mechanisms underlying the immune dysfunction are not yet fully understood. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Recombinant Antibody Microarray for Profiling the Serum Proteome of SLE
Systemic lupus erythematosus (SLE) is a severe autoimmune connective tissue disease. Our current knowledge about the serum proteome, or serum biomarker panels, reflecting disease and disease status is still very limited. Affinity proteomics, represented by recombinant antibody arrays, is a novel, multiplex technology for high-throughput protein expression profiling of crude serum proteomes in a highly specific, sensitive, and miniaturized manner. The antibodies are deposited one by one in an ordered pattern, an array, onto a solid support. Next, the sample is added, and any specifically bound proteins are detected and quan...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Detection of Antinuclear Antibodies in SLE
The antinuclear antibodies (ANA) also known as antinuclear factors (ANF) are unwanted molecules which bind and destroy certain structures within the nucleus. In systemic lupus erythematosus (SLE), they are produced in excess; hence their detection in the blood of patients is important for diagnosis and monitoring of the disease. Several methods are available which can be used to detect ANA; nevertheless, indirect immunofluorescence antinuclear antibody test (IF-ANA) is considered a “reference method” for their detection. Though IF-ANA is relatively easier to perform, its interpretation requires considerable ski...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Tests for Circulating Immune Complexes
Antigen–antibody complexes in tissues play a central role in the pathogenesis of lupus. Some of the immune complexes are formed in situ, i.e., in the tissues. Others are present in the blood stream, and these circulating immune complexes may deposit in tissues and incite inflammatory mechanisms in those tissues. A variety of techniques are available to measure circulating immune complexes. The assays that have been most studied in SLE include approaches that rely on the interaction of immune complexes with complement proteins, and therefore bind to C1q or contain bound C3. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Delist gray wolf from threatened and endangered list? Panel issues report on science
As the Endangered Species Act celebrated its 40th anniversary at the end of 2013, its administrative agency, the US Fish and Wildlife Service, was mired in controversy. At issue was a proposal to remove the gray wolf (Canis lupus) from the List of Endangered and Threatened Wildlife and add the Mexican gray wolf (Canis lupus baileyi). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2014 Category: Science Source Type: news

Panel issues report on gray wolf science
(University of California - Santa Barbara) As the Endangered Species Act celebrated its 40th anniversary at the end of 2013, its administrative agency, the US Fish and Wildlife Service, was mired in controversy. At issue was a proposal to remove the gray wolf (Canis lupus) from the List of Endangered and Threatened Wildlife and add the Mexican gray wolf (Canis lupus baileyi). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 7, 2014 Category: Biology Source Type: news